CTOs on the Move

Checkerspot

www.checkerspot.com

 
Checkerspot is a design-centric materials company enabling ultra-high performance consumer products.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Checkerspot raised $13M on 04/16/2019

Similar Companies

Hawaii Chitopure

Hawaii Chitopure is a Honolulu, HI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cerno Bioscience

Cerno Bioscience is a company that develops and publishes mass spectrometry calibration and analysis software that extends the limits of mass spectrometry.

Akoya Biosciences

As The Spatial Biology Company®, Akoya Biosciences` mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments.

Crinetics

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company`s lead product candidate, paltusotine (formerly CRN00808), is an investigational, oral, selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 26,000 people in the United States. A Phase 3 program in acromegaly with paltusotine is underway. Crinetics also plans to advance paltusotine into a Phase 2 trial for the treatment of carcinoid syndrome associated with neuroendocrine tumors. The company is also developing CRN04777, an investigational, oral, nonpeptide somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, as well as CRN04894, an investigational, oral, nonpeptide ACTH antagonist for the treatment of Cushing`s disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company`s drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company.

TransDermal Technologies Inc

TransDermal Technologies Inc is a North Palm Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.